	US 11,873,310 B2
	Compounds useful in HIV therapy
Vincent Wing-Fai Tai, Research Triangle Park, NC (US); and Jun Tang, Research Triangle Park, NC (US)
Assigned to GlaxoSmithKline Intellectual Property Development Limited, Stevenage (GB)
Filed by GlaxoSmithKline Intellectual Property Development Limited, Stevenage (GB)
Filed on Aug. 6, 2021, as Appl. No. 17/395,723.
Application 17/395,723 is a continuation of application No. 16/948,873, filed on Oct. 5, 2020, granted, now 11,492,361.
Application 16/948,873 is a continuation of application No. 16/897,351, filed on Jun. 10, 2020, granted, now 10,870,663, issued on Dec. 22, 2020.
Application 16/897,351 is a continuation of application No. 16/621,312, previously published as PCT/IB2019/060267, filed on Nov. 28, 2019.
Claims priority of provisional application 62/773,563, filed on Nov. 30, 2018.
Prior Publication US 2022/0119417 A1, Apr. 21, 2022
Int. Cl. C07D 519/00 (2006.01); A61P 31/18 (2006.01)

CPC C07D 519/00 (2013.01) [A61P 31/18 (2018.01)]

4 Claims

1. A compound of the formula:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound according to claim 1 or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.